Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298479 | 0.98 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 | |
| SCHEMBL18196618 | 0.88 | SMN1; SMN2 (0.74) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 | |
| SCHEMBL10587847 | 0.87 | ALDH1A1 (0.83) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 | |
| SCHEMBL11036812 | 0.83 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1HPGDEPHX1NPC1 | |
| SCHEMBL19784240 | 0.82 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 | |
| SCHEMBL172009 | 0.81 | EPHX1 (0.59) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 | |
| SCHEMBL10132085 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 | |
| SCHEMBL23419601 | 0.79 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 | |
| SCHEMBL12292825 | 0.79 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 | |
| SCHEMBL19849412 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | claimed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | claimed |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20050261274-A1 | Lactams substituted by cyclic succinates as inhibitors of Abeta protein production | OLSON RICHARD E | 2005-11-24 | — | — | US | disclosed |
| US-6958329-B2 | Lactams substituted by cyclic succinates as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-06-26 | — | — | US | disclosed |
| US-6509333-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-21 | — | — | US | disclosed |
| EP-1268450-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-26 | — | — | US | disclosed |
| WO-2001092235-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | APP, BACE1, APH1A | SMN1; SMN2 317/4885ALDH1A1 2891/4885HPGD 956/4885 |
| US-20050261274-A1 | Lactams substituted by cyclic succinates as inhibitors of Abeta protein production | BACE1, APP, APH1A | SMN1; SMN2 520/4885ALDH1A1 3203/4885HPGD 960/4885 |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BACE1, APP, APH1A | SMN1; SMN2 520/4885ALDH1A1 3203/4885HPGD 960/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | SMN1; SMN2 609/4885ALDH1A1 2423/4885HPGD 1633/4885 |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | APH1A, APH1B, APP | SMN1; SMN2 378/4885ALDH1A1 2245/4885HPGD 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.